

# W Ray Kim

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3846970/w-ray-kim-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

217  
papers

20,511  
citations

71  
h-index

142  
g-index

248  
ext. papers

23,837  
ext. citations

6.7  
avg, IF

6.85  
L-index

#	Paper	IF	Citations
217	Author response to "MELD 3.0: The Model for End-stage Liver Disease Updated for the Modern Era".. <i>Gastroenterology</i> , <b>2022</b> ,	13.3	
216	Targeted Electronic Patient Portal Messaging Increases Hepatitis C Virus Screening in Primary Care: a Randomized Study.. <i>Journal of General Internal Medicine</i> , <b>2022</b> , 1	4	
215	"Beyond MELD" - Emerging strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation.. <i>Journal of Hepatology</i> , <b>2022</b> , 76, 1318-1329	13.4	0
214	An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign-Born Persons Living in the United States. <i>Hepatology</i> , <b>2021</b> , 74, 607-626	11.2	20
213	Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , <b>2021</b> , 74, 1014-1048	11.2	45
212	Introducing EL-FIT (Exercise and Liver FITness): A Smartphone App to Prehabilitate and Monitor Liver Transplant Candidates. <i>Liver Transplantation</i> , <b>2021</b> , 27, 502-512	4.5	10
211	Feasibility and Effectiveness of Norepinephrine Outside the Intensive Care Setting for Treatment of Hepatorenal Syndrome. <i>Liver Transplantation</i> , <b>2021</b> , 27, 1095-1105	4.5	4
210	MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. <i>Gastroenterology</i> , <b>2021</b> , 161, 1887-1895.e4	13.3	11
209	Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	3
208	Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation. <i>Hepatology Communications</i> , <b>2021</b> , 5, 516-525	6	2
207	Cost- Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease. <i>ClinicoEconomics and Outcomes Research</i> , <b>2020</b> , 12, 515-526	1.7	6
206	Development of Hepatocellular Carcinoma in Patients With Suppressed Viral Replication: Changes in Risk Over Time. <i>Clinical Liver Disease</i> , <b>2020</b> , 15, 85-90	2.2	5
205	Cadence From Physical Activity Trackers for Monitoring of Home-Based Exercise Intensity in Advanced Liver Disease. <i>Liver Transplantation</i> , <b>2020</b> , 26, 718-721	4.5	5
204	Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine. <i>Hepatology</i> , <b>2020</b> , 72, 2197-2205	11.2	12
203	Tool to Aid Patients in Selecting a Liver Transplant Center. <i>Liver Transplantation</i> , <b>2020</b> , 26, 337-348	4.5	3
202	Exercise-Induced Hyperammonemia Does Not Precipitate Overt Hepatic Encephalopathy. <i>Hepatology</i> , <b>2020</b> , 72, 778-780	11.2	2
201	Introduction: Liver Disease in Asia. <i>Clinical Liver Disease</i> , <b>2020</b> , 16, 223-226	2.2	78

200	Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> ,	6.9	4
199	Home-Based Physical Activity and Diet Intervention to Improve Physical Function in Advanced Liver Disease: A Randomized Pilot Trial. <i>Digestive Diseases and Sciences</i> , <b>2020</b> , 65, 3350-3359	4	19
198	Reply to: "The decreasing predictive power of MELD in an era of changing etiology of liver disease". <i>American Journal of Transplantation</i> , <b>2020</b> , 20, 901-902	8.7	3
197	Defining a Willingness-to-transplant Threshold in an Era of Organ Scarcity: Simultaneous Liver-kidney Transplant as a Case Example. <i>Transplantation</i> , <b>2020</b> , 104, 387-394	1.8	8
196	Center Variation in Intention-to-Treat Survival Among Patients Listed for Liver Transplant. <i>Liver Transplantation</i> , <b>2020</b> , 26, 1582-1593	4.5	4
195	Prevalence of Chronic Hepatitis B Virus Infection in the United States. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 1429-1438	0.7	32
194	Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 747-749	6.9	10
193	The interaction of nonalcoholic fatty liver disease and smoking on mortality among adults in the United States. <i>Liver International</i> , <b>2019</b> , 39, 1202-1206	7.9	2
192	Impact of Sofosbuvir-Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection. <i>Pharmacotherapy</i> , <b>2019</b> , 39, 424-432	5.8	0
191	Migration of Patients for Liver Transplantation and Waitlist Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2347-2355.e5	6.9	3
190	Diagnosis and Management of Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 48-63	0.7	41
189	A Comparison Between Community and Academic Practices in the USA in the Management of Chronic Hepatitis B Patients Receiving Entecavir: Results of the ENUMERATE Study. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 358-366	4	4
188	De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era. <i>Hepatology</i> , <b>2018</b> , 68, 1288-1297	11.2	7
187	Liver Simulated Allocation Modeling: Were the Predictions Accurate for Share 35?. <i>Transplantation</i> , <b>2018</b> , 102, 769-774	1.8	9
186	Improved posttransplant mortality after share 35 for liver transplantation. <i>Hepatology</i> , <b>2018</b> , 67, 273-281	11.2	33
185	Nonalcoholic Fatty Liver Disease and Metabolic Syndrome. <i>Clinics in Liver Disease</i> , <b>2018</b> , 22, 133-140	4.6	104
184	Exercise and physical activity for patients with end-stage liver disease: Improving functional status and sarcopenia while on the transplant waiting list. <i>Liver Transplantation</i> , <b>2018</b> , 24, 122-139	4.5	92
183	Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. <i>Hepatology</i> , <b>2018</b> , 68, 78-88	11.2	28

182	Long-term Patient and Graft Survival of Kidney Transplant Recipients With Hepatitis C Virus Infection in the United States. <i>Transplantation</i> , <b>2018</b> , 102, 454-460	1.8	25
181	Short Sleep Duration Is Associated With Abnormal Serum Aminotransferase Activities and Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 588-590	6.9	9
180	Comparing Simultaneous Liver-Kidney Transplant Strategies: A Modified Cost-Effectiveness Analysis. <i>Transplantation</i> , <b>2018</b> , 102, e219-e228	1.8	6
179	Epidemiology of Hepatitis B Virus Infection in the United States. <i>Clinical Liver Disease</i> , <b>2018</b> , 12, 1-4	2.2	26
178	Reduced Access to Liver Transplantation in Women: Role of Height, MELD Exception Scores, and Renal Function Underestimation. <i>Transplantation</i> , <b>2018</b> , 102, 1710-1716	1.8	48
177	Hepatitis B Virus Reactivation and Management of Patients Undergoing Immunosuppression <b>2018</b> , 315-341		
176	Decreasing mortality and disease severity in hepatitis C patients awaiting liver transplantation in the United States. <i>Liver Transplantation</i> , <b>2018</b> , 24, 735-743	4.5	17
175	Longitudinal trends in renal function in chronic hepatitis B patients receiving oral antiviral treatment. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 1282-1289	6.1	13
174	Hemoglobin A1c Has Suboptimal Performance to Diagnose and Monitor Diabetes Mellitus in Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 3498-3508	4	4
173	Natural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era: Role of Scoring Systems. <i>Clinics in Liver Disease</i> , <b>2018</b> , 22, 563-578	4.6	17
172	Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates. <i>Liver Transplantation</i> , <b>2017</b> , 23, 733-740	4.5	23
171	Inequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-stage liver disease. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 517-525	13.4	22
170	Utility in Treating Kidney Failure in End-Stage Liver Disease With Simultaneous Liver-Kidney Transplantation. <i>Transplantation</i> , <b>2017</b> , 101, 1111-1119	1.8	20
169	Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B. <i>American Journal of Epidemiology</i> , <b>2017</b> , 186, 356-366	3.8	7
168	Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. <i>Hepatology</i> , <b>2017</b> , 65, 804-812	11.2	160
167	Nonobese Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 474-485	6.9	191
166	Renal Complications of Liver Disease and the Hepatorenal Syndrome <b>2017</b> , 336-352		
165	Impact of direct-acting antiviral agents-induced SVR on the long-term burden of hepatocellular carcinoma in chronic hepatitis C cirrhosis.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 230-230	2.2	

164	Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 1573-1580	0.7	43
163	Management of renal failure in end-stage liver disease: A critical appraisal. <i>Liver Transplantation</i> , <b>2016</b> , 22, 1710-1719	4.5	6
162	Predicting Outcomes on the Liver Transplant Waiting List in the United States: Accounting for Large Regional Variation in Organ Availability and Priority Allocation Points. <i>Transplantation</i> , <b>2016</b> , 100, 2153-9	1.8	21
161	Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 1297-304	0.7	32
160	Increasing prevalence of cirrhosis among U.S. adults aware or unaware of their chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 1027-1032	13.4	43
159	Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. <i>Gastroenterology</i> , <b>2016</b> , 150, 684-695.e5	13.3	126
158	The Epidemiology of Liver Diseases Unique to Pregnancy in a US Community: A Population-Based Study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 287-94.e1-2	6.9	42
157	Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 773-80	13.4	169
156	Potential Efficacy of Pegylated Interferon- $\alpha$ and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B. <i>Gut and Liver</i> , <b>2016</b> , 10, 611-6	4.8	3
155	Epidemiology and Healthcare Burden of Acute-on-Chronic Liver Failure. <i>Seminars in Liver Disease</i> , <b>2016</b> , 36, 123-6	7.3	14
154	Time trends in the health care burden and mortality of acute on chronic liver failure in the United States. <i>Hepatology</i> , <b>2016</b> , 64, 2165-2172	11.2	85
153	Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 134-44	6.1	49
152	Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States. <i>Hepatology</i> , <b>2015</b> , 61, 1643-50	11.2	85
151	Reply to: "Chronic kidney disease (CKD) and NAFLD: time for awareness and screening". <i>Journal of Hepatology</i> , <b>2015</b> , 62, 984-5	13.4	2
150	Corrigendum to Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites [J Hepatol 2015;62:968-74]. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 290	13.4	5
149	Reply to: "Chronic kidney disease after liver transplantation". <i>Journal of Hepatology</i> , <b>2015</b> , 62, 244-5	13.4	
148	Current and Future Burden of Chronic Nonmalignant Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 2031-41	6.9	88
147	Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 183-92	6.9	68

146	Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. <i>Liver Transplantation</i> , <b>2015</b> , 21, 248-57	4.5	25
145	Diabetes and prediabetes in patients with hepatitis B residing in North America. <i>Hepatology</i> , <b>2015</b> , 62, 1364-74	11.2	19
144	Serum Cystatin C as an Indicator of Renal Function and Mortality in Liver Transplant Recipients. <i>Transplantation</i> , <b>2015</b> , 99, 1431-5	1.8	26
143	Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. <i>Cancer</i> , <b>2015</b> , 121, 3631-8	6.4	125
142	Low level of hepatitis B virus screening among patients receiving chemotherapy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 970-5; quiz e51	6.9	20
141	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <i>Gut</i> , <b>2015</b> , 64, 531-7	19.2	247
140	Reply to Prediction of hepatocellular carcinoma: using a complex risk model or assisting for smoking cessation?. <i>Cancer</i> , <b>2015</b> , 121, 1150	6.4	
139	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 968-74	13.4	391
138	Korean Version of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma (K-MESIAH). <i>PLoS ONE</i> , <b>2015</b> , 10, e0138374	3.7	1
137	The impact of hepatitis C burden: an evidence-based approach. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 518-31	6.1	97
136	Comparative effectiveness of telaprevir-based triple therapy in patients with chronic hepatitis C. <i>Mayo Clinic Proceedings</i> , <b>2014</b> , 89, 595-601	6.4	3
135	Chronic kidney disease and associated mortality after liver transplantation--a time-dependent analysis using measured glomerular filtration rate. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 286-92	13.4	102
134	Management of hepatic encephalopathy in the hospital. <i>Mayo Clinic Proceedings</i> , <b>2014</b> , 89, 241-53	6.4	74
133	Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. <i>Hepatology</i> , <b>2014</b> , 60, 2008-16	11.2	107
132	Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. <i>Cancer</i> , <b>2014</b> , 120, 3485-93	6.4	93
131	Effect of the pretransplant serum sodium concentration on outcomes following liver transplantation. <i>Liver Transplantation</i> , <b>2014</b> , 20, 687-97	4.5	30
130	Validation of a model to estimate survival in ambulatory patients with hepatocellular carcinoma: a single-centre cohort study. <i>Liver International</i> , <b>2014</b> , 34, e317-23	7.9	17
129	Survival of recipients of livers from donation after circulatory death who are relisted and undergo retransplant for graft failure. <i>American Journal of Transplantation</i> , <b>2014</b> , 14, 1120-8	8.7	14

128	Impact of the center on graft failure after liver transplantation. <i>Liver Transplantation</i> , <b>2013</b> , 19, 957-64	4.5	35
127	Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2013</b> , 11, 1655-60.e1	6.9	11
126	Predicting clinical outcomes with elastography in primary biliary cirrhosis: one step closer?. <i>Gastroenterology</i> , <b>2013</b> , 144, 851-2	13.3	1
125	Underestimation of liver-related mortality in the United States. <i>Gastroenterology</i> , <b>2013</b> , 145, 375-82.e1-2	23.3	195
124	Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. <i>Hepatology</i> , <b>2013</b> , 57, 648-55	11.2	94
123	Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. <i>Radiology</i> , <b>2013</b> , 268, 411-9	20.5	171
122	Excellent quality of life after liver transplantation for patients with perihilar cholangiocarcinoma who have undergone neoadjuvant chemoradiation. <i>Liver Transplantation</i> , <b>2013</b> , 19, 521-8	4.5	21
121	Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. <i>Hepatology</i> , <b>2013</b> , 57, 1357-65	11.2	459
120	Hepatitis B screening and vaccination practices in asian american primary care. <i>Gut and Liver</i> , <b>2013</b> , 7, 450-7	4.8	19
119	Simultaneous liver-kidney transplantation summit: current state and future directions. <i>American Journal of Transplantation</i> , <b>2012</b> , 12, 2901-8	8.7	189
118	Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. <i>Liver Transplantation</i> , <b>2012</b> , 18, 323-31	4.5	58
117	Surveillance for hepatocellular carcinoma in patients with cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2012</b> , 10, 16-21	6.9	22
116	Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008. <i>Mayo Clinic Proceedings</i> , <b>2012</b> , 87, 9-16	6.4	33
115	Hospitalization for underage drinkers in the United States. <i>Journal of Adolescent Health</i> , <b>2012</b> , 50, 648-50	9.8	14
114	Evaluation of elevated liver enzymes. <i>Clinics in Liver Disease</i> , <b>2012</b> , 16, 183-98	4.6	36
113	Kidney, pancreas and liver allocation and distribution in the United States. <i>American Journal of Transplantation</i> , <b>2012</b> , 12, 3191-212	8.7	87
112	Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. <i>Gastroenterology</i> , <b>2012</b> , 143, 88-98.e3; quiz e14	13.3	353
111	Development of organ-specific donor risk indices. <i>Liver Transplantation</i> , <b>2012</b> , 18, 395-404	4.5	53

110	Nonalcoholic fatty liver disease is associated with coronary artery calcification. <i>Hepatology</i> , <b>2012</b> , 56, 605-13	11.2	220
109	Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. <i>Hepatology</i> , <b>2012</b> , 56, 972-81	11.2	96
108	Model to estimate survival in ambulatory patients with hepatocellular carcinoma. <i>Hepatology</i> , <b>2012</b> , 56, 614-21	11.2	67
107	Hepatitis B screening in a US academic primary care practice. <i>Archives of Internal Medicine</i> , <b>2012</b> , 172, 1517-9		1
106	Biliary tract cancers in Olmsted County, Minnesota, 1976-2008. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 1256-62	0.7	53
105	Impact of Obesity on Alcoholic Hepatitis: A Population Based Study. <i>Gastroenterology</i> , <b>2011</b> , 140, S-914	13.3	2
104	A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. <i>Gastroenterology</i> , <b>2011</b> , 140, 1952-60	13.3	102
103	Born to be wild or just confused? Genetic predisposition to hepatic encephalopathy. <i>Gastroenterology</i> , <b>2011</b> , 140, 2137-8	13.3	
102	Model for end-stage liver disease: end of the first decade. <i>Clinics in Liver Disease</i> , <b>2011</b> , 15, 685-98	4.6	39
101	Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , <b>2011</b> , 9, 434-9.e1	6.9	92
100	Drug therapy: telaprevir. <i>Hepatology</i> , <b>2011</b> , 54, 1463-9	11.2	4
99	Factors that affect risk for hepatocellular carcinoma and effects of surveillance. <i>Clinical Gastroenterology and Hepatology</i> , <b>2011</b> , 9, 617-23.e1	6.9	99
98	Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , <b>2011</b> , 9, 64-70	6.9	170
97	Treatment of hepatitis B virus-associated nephropathy. <i>Nephron Clinical Practice</i> , <b>2011</b> , 119, c41-9; discussion c49		37
96	The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. <i>Journal of Medical Economics</i> , <b>2011</b> , 14, 253-61	2.4	55
95	Issues in Transplantation of Patients with Chronic Liver Failure <b>2011</b> , 521-539		
94	Hepatitis B and C <b>2010</b> , 186-199		
93	Alcoholic liver disease-related mortality in the United States: 1980-2003. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 1782-7	0.7	64



92	Endothelial nitric oxide synthase gene variation associated with chronic kidney disease after liver transplant. <i>Mayo Clinic Proceedings</i> , <b>2010</b> , 85, 814-20	6.4	2
91	Donor race does not predict graft failure after liver transplantation. <i>Gastroenterology</i> , <b>2010</b> , 138, 2341-7	13.3	18
90	Predicting response to pegylated interferon/ribavirin-based therapy in genotype 1 chronic hepatitis C patients: results of 3 independent genome-wide association studies. <i>Gastroenterology</i> , <b>2010</b> , 138, 1622-4	13.3	4
89	Rifaximin in hepatic encephalopathy: is an ounce of prevention worth a pretty penny?. <i>Gastroenterology</i> , <b>2010</b> , 139, 1416-8	13.3	2
88	Serum sodium, renal function, and survival of patients with end-stage liver disease. <i>Journal of Hepatology</i> , <b>2010</b> , 52, 523-8	13.4	53
87	Humanistic and economic impacts of hepatitis C infection in the United States. <i>Journal of Medical Economics</i> , <b>2010</b> , 13, 709-18	2.4	67
86	Organ allocation for chronic liver disease: model for end-stage liver disease and beyond. <i>Current Opinion in Gastroenterology</i> , <b>2010</b> , 26, 209-13	3	24
85	Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C. <i>Journal of Clinical Gastroenterology</i> , <b>2010</b> , 44, e178-85	3	17
84	Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis. <i>Hepatology</i> , <b>2010</b> , 52, 1360-70	11.2	61
83	Utility of Serum YKL-40 as a Tumor-Specific Marker of Hepatobiliary Malignancies. <i>Gut and Liver</i> , <b>2010</b> , 4, 537-42	4.8	3
82	Reports from today's health care environment on the implementation of screening, diagnosis, and treatment recommendations. <i>Journal of Family Practice</i> , <b>2010</b> , 59, S43-50	0.2	1
81	Transforming the current infrastructure for combating HBV and HCV infections. <i>Journal of Family Practice</i> , <b>2010</b> , 59, S65-70	0.2	2
80	Impact of pretransplant hyponatremia on outcome following liver transplantation. <i>Hepatology</i> , <b>2009</b> , 49, 1610-5	11.2	92
79	Epidemiology of hepatitis B in the United States. <i>Hepatology</i> , <b>2009</b> , 49, S28-34	11.2	147
78	Hepatitis C nonresponders: re-treat or retreat?. <i>Hepatology</i> , <b>2009</b> , 50, 1307-9	11.2	1
77	The Clip score: is it time to be clipped away?. <i>Liver International</i> , <b>2009</b> , 29, 2-3	7.9	1
76	Increased prevalence and mortality in undiagnosed celiac disease. <i>Gastroenterology</i> , <b>2009</b> , 137, 88-93	13.3	548
75	Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. <i>Gastroenterology</i> , <b>2009</b> , 137, 1680-6	13.3	131

74	Hyponatremia in hepatic encephalopathy: an accomplice or innocent bystander?. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 1390-1	0.7	9
73	The international normalized ratio of prothrombin time in the model for end-stage liver disease score: a reliable measure. <i>Clinics in Liver Disease</i> , <b>2009</b> , 13, 63-66	4.6	7
72	The global impact of hepatic fibrosis and end-stage liver disease. <i>Clinics in Liver Disease</i> , <b>2008</b> , 12, 733-46, vii	4.6	218
71	Hepatic vein pressure gradient >10 mm Hg: prognostic or reflective?. <i>Gastroenterology</i> , <b>2008</b> , 134, 641; author reply 641-2	13.3	2
70	Clinical implications of short-term variability in liver function test results. <i>Gastroenterology</i> , <b>2008</b> , 135, 1010-1; discussion 1011-2	13.3	3
69	Hyponatremia and mortality among patients on the liver-transplant waiting list. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 1018-26	59.2	875
68	Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. <i>Gut</i> , <b>2008</b> , 57, 814-20	19.2	180
67	Mortality attributable to cholestatic liver disease in the United States. <i>Hepatology</i> , <b>2008</b> , 47, 1241-7	11.2	30
66	Serum aminotransferase activity and mortality risk in a United States community. <i>Hepatology</i> , <b>2008</b> , 47, 880-7	11.2	119
65	Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. <i>Hepatology</i> , <b>2008</b> , 47, 1363-70	11.2	480
64	Reply:. <i>Hepatology</i> , <b>2008</b> , 48, 688-688	11.2	2
63	Natural history of hepatitis B virus infection: an update for clinicians. <i>Mayo Clinic Proceedings</i> , <b>2007</b> , 82, 967-75	6.4	151
62	Risk factors for mortality after surgery in patients with cirrhosis. <i>Gastroenterology</i> , <b>2007</b> , 132, 1261-9	13.3	386
61	The model for end-stage liver disease (MELD). <i>Hepatology</i> , <b>2007</b> , 45, 797-805	11.2	1060
60	Survival after liver transplantation: Is racial disparity inevitable?. <i>Hepatology</i> , <b>2007</b> , 46, 1491-7	11.2	19
59	Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. <i>Liver Transplantation</i> , <b>2007</b> , 13, 1366-71	4.5	185
58	Can the model for end-stage liver disease be used to predict the prognosis in patients with Budd-Chiari syndrome?. <i>Liver Transplantation</i> , <b>2007</b> , 13, 867-74	4.5	27
57	Epidemiology of hepatitis B in the United States. <i>Current Hepatitis Reports</i> , <b>2007</b> , 6, 3-8		

56	Deaths on the liver transplant waiting list: an analysis of competing risks. <i>Hepatology</i> , <b>2006</b> , 43, 345-51	11.2	114
55	Is coffee or tea good for your liver?. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , <b>2006</b> , 3, 482-3		2
54	Evidence-based incorporation of serum sodium concentration into MELD. <i>Gastroenterology</i> , <b>2006</b> , 130, 1652-60	13.3	506
53	The use of decision analytic models to inform clinical decision making in the management of hepatocellular carcinoma. <i>Clinics in Liver Disease</i> , <b>2005</b> , 9, 225-34	4.6	
52	Mortality and Hospital Utilization for Hepatocellular Carcinoma in the United States. <i>Gastroenterology</i> , <b>2005</b> , 129, 486-493	13.3	0
51	Mortality and hospital utilization for hepatocellular carcinoma in the United States. <i>Gastroenterology</i> , <b>2005</b> , 129, 486-93	13.3	86
50	Employment and health insurance in long-term liver transplant recipients. <i>American Journal of Transplantation</i> , <b>2005</b> , 5, 1901-8	8.7	34
49	MELD accurately predicts mortality in patients with alcoholic hepatitis. <i>Hepatology</i> , <b>2005</b> , 41, 353-8	11.2	353
48	Reply:. <i>Hepatology</i> , <b>2005</b> , 42, 495-496	11.2	1
47	Health Status Assessment and Economic Analyses in Cirrhosis and Portal Hypertension <b>2005</b> , 469-484		
46	Liver Transplantation for Primary Biliary Cirrhosis <b>2005</b> , 177-186		
45	Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat. <i>Annals of Family Medicine</i> , <b>2004</b> , 2, 116-24	2.9	37
44	Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. <i>American Journal of Transplantation</i> , <b>2004</b> , 4, 1798-804	8.7	91
43	MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. <i>Hepatology</i> , <b>2004</b> , 39, 764-9	11.2	171
42	Changing epidemiology of hepatitis B in a U.S. community. <i>Hepatology</i> , <b>2004</b> , 39, 811-6	11.2	65
41	Outcome of liver transplantation for hepatitis B in the United States. <i>Liver Transplantation</i> , <b>2004</b> , 10, 968-74	4.5	156
40	The impact of competing risks on the observed rate of chronic hepatitis C progression. <i>Gastroenterology</i> , <b>2004</b> , 127, 749-55	13.3	24
39	Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae?. <i>Journal of Hepatology</i> , <b>2004</b> , 40, 380-4	13.4	85

38	A glossary of economic terms. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2004</b> , 16, 563-5	2.2	4
37	Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2004</b> , 16, 519-26	2.2	27
36	Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. <i>Hepatology</i> , <b>2003</b> , 37, 897-901	11.2	158
35	Effect of minimal listing criteria on waiting list registration for liver transplantation: a process-outcome analysis. <i>Mayo Clinic Proceedings</i> , <b>2003</b> , 78, 431-5	6.4	5
34	Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. <i>Gastroenterology</i> , <b>2003</b> , 125, 1364-9	13.3	328
33	Motion - the available treatments for hepatitis C are cost effective: arguments against the motion. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2002</b> , 16, 710-5		3
32	Bayesian estimation, simulation and uncertainty analysis: the cost-effectiveness of ganciclovir prophylaxis in liver transplantation. <i>Health Economics (United Kingdom)</i> , <b>2002</b> , 11, 551-66	2.4	10
31	The burden of hepatitis C in the United States. <i>Hepatology</i> , <b>2002</b> , 36, S30-S34	11.2	283
30	Global epidemiology and burden of hepatitis C. <i>Microbes and Infection</i> , <b>2002</b> , 4, 1219-25	9.3	107
29	The burden of hepatitis C in the United States. <i>Hepatology</i> , <b>2002</b> , 36, S30-4	11.2	205
28	Medical and economic impact of autoimmune hepatitis. <i>Clinics in Liver Disease</i> , <b>2002</b> , 6, 649-67	4.6	7
27	Development and maintenance of a community-based hepatitis C registry. <i>American Journal of Managed Care</i> , <b>2002</b> , 8, 253-61	2.1	5
26	Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. <i>Journal of Family Practice</i> , <b>2002</b> , 51, 135-40	0.2	28
25	Outcome of hospital care of liver disease associated with hepatitis C in the United States. <i>Hepatology</i> , <b>2001</b> , 33, 201-6	11.2	73
24	A model to predict survival in patients with end-stage liver disease. <i>Hepatology</i> , <b>2001</b> , 33, 464-70	11.2	3267
23	MELD and PELD: application of survival models to liver allocation. <i>Liver Transplantation</i> , <b>2001</b> , 7, 567-80	4.5	653
22	Models predicting the natural history of cirrhosis and need for liver transplantation. <i>Current Opinion in Organ Transplantation</i> , <b>2001</b> , 6, 107-113	2.5	3
21	A Revised Natural History Model for Primary Sclerosing Cholangitis. <i>Mayo Clinic Proceedings</i> , <b>2000</b> , 75, 688-694	6.4	203

20	Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C. <i>Hepatology</i> , <b>2000</b> , 31, 807-8	11.2	6
19	Reliability and validity of the NIDDK-QA instrument in the assessment of quality of life in ambulatory patients with cholestatic liver disease. <i>Hepatology</i> , <b>2000</b> , 32, 924-9	11.2	33
18	Predicting clinical and economic outcomes after liver transplantation using the Mayo primary sclerosing cholangitis model and Child-Pugh score. National Institutes of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database Group. <i>Liver Transplantation</i> , <b>2000</b> , 6, 753-8	4.5	28
17	Adaptation of the Mayo primary biliary cirrhosis natural history model for application in liver transplant candidates. <i>Liver Transplantation</i> , <b>2000</b> , 6, 489-94	4.5	42
16	Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. <i>Liver Transplantation</i> , <b>2000</b> , 6, 453-8	4.5	144
15	Timing of liver transplantation. <i>Seminars in Liver Disease</i> , <b>2000</b> , 20, 451-64	7.3	8
14	A revised natural history model for primary sclerosing cholangitis. <i>Mayo Clinic Proceedings</i> , <b>2000</b> , 75, 688-94	6.4	221
13	The economic impact of cytomegalovirus infection after liver transplantation. <i>Transplantation</i> , <b>2000</b> , 69, 357-61	1.8	65
12	Quality of life before and after liver transplantation for cholestatic liver disease. <i>Hepatology</i> , <b>1999</b> , 29, 356-64	11.2	148
11	The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. <i>Hepatology</i> , <b>1999</b> , 29, 1643-8	11.2	104
10	Hepatic retransplantation in cholestatic liver disease: impact of the interval to retransplantation on survival and resource utilization. <i>Hepatology</i> , <b>1999</b> , 30, 395-400	11.2	56
9	Optimal timing of liver transplantation for primary biliary cirrhosis. <i>Hepatology</i> , <b>1998</b> , 28, 33-8	11.2	83
8	Predictive models of natural history in primary biliary cirrhosis. <i>Clinics in Liver Disease</i> , <b>1998</b> , 2, 313-31, ix	4.6	7
7	The role of prognostic models in the timing of liver transplantation. Application in cholestatic liver diseases. <i>Clinics in Liver Disease</i> , <b>1997</b> , 1, 263-79, vii	4.6	3
6	Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. <i>Hepatology</i> , <b>1997</b> , 26, 22-6	11.2	86
5	Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. <i>Annals of Internal Medicine</i> , <b>1997</b> , 127, 866-74	8	116
4	Recurrence of nonalcoholic steatohepatitis following liver transplantation. <i>Transplantation</i> , <b>1996</b> , 62, 1802-5	1.8	133
3	Hepatitis B and C254-260		

2 Epidemiology of Hepatitis B and C in the United States 322-331

1 Session 2: Predictive Models in Portal Hypertension 47-102

9